Cargando…
Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
Psoriasis is a common chronic immune-mediated skin disease, with systemic involvement and significant impact in patients’ quality of life. Several highly specific treatments have been developed over the years, such as tumor necrosis factor-α inhibitors, a nonselective IL-23 inhibitor (ustekinumab),...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6239126/ https://www.ncbi.nlm.nih.gov/pubmed/30519540 http://dx.doi.org/10.2147/PTT.S165943 |